A Rueda Naharro

Results 12 patients were included (92% men), median age 58 years (range 25–78). Diagnosis: 41% dyslipidaemia, 25% hypercholesterolaemia, 17% hyperlipidaemia and 17% heart disease. 50% patients received arilocumab and 50% evolocumab. All patients had been treated with statins before mAb therapy. In 42% of cases statins had to be removed, mainly because of myositis (80%). The remainder of the patients were not statin-intolerant but LDL-c goals were not achieved.